Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer

International Journal of Biological Markers

Volumn 23, Issue 4, 2008, Pages 244-248

  Tsai, H L ^a,b   Chang, Y T ^b   Chu, K S ^b,c   Chen, C F ^b,d   Yeh, Y S ^a,b   Ma, C J ^b   Wu, D C ^b,c   Kuo, C H ^b,c   Chan, H M ^b,c   Sheen, M C ^b,c   Wang, Jaw Yuan ^b,c  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Pingtung Hospital   (Taiwan)

Author keywords

Carcinoembryonic antigen; Cetuximab; Metastatic colorectal cancer; Response

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FOLFOX PROTOCOL; FOLFOXIRI PROTOCOL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT MONITORING; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BLOOD; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65349119480     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.4266     Document Type: Article

References (24)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
2. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
3. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-21.
4. Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd; Eastern Cooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17: 1399-403.
5. Tabernero J, Van Cutsem E, Díaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-32.
6. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-9.
7. Arnold D, Höhler T, Dittrich C, et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008; 19: 1442-9.
8. Lal R, Dickson J, Cunningham D, et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor- resistant advanced colorectal cancer. J Clin Cncol 2004; 22: 3023-31.
9. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122: 467-81.
10. Ward U, Primrose JN, Finan PJ, et al. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993; 67: 1132-5.
11. Grem JL, Steinberg SM, Chen AP, et al. The utility of monitoring carcinoembryonic antigen during systemic therapy for advanced colorectal cancer. Oncol Rep 1998; 5: 559-67.
12. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786-95.
13. Hanke B, Riedel C, Lampert S, et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 2001; 12: 221-6.
14. Wang WS, Lin JK, Lin TC, et al. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer. Int J Colorectal Dis 2001; 16: 96-101.
15. Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 2002; 13: 1430-7.
16. Yamao T, Kai S, Kazami A, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999; 29: 550-5.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
18. World Health Organization: WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.
19. Sugarbaker PH, Skarin AT, Zamcheck N. Patterns of serial CEA assays and their clinical use in management of colorectal cancer. J Surg Oncol 1976; 8: 523-37.
20. Herrera MA, Chu TM, Holyoke ED, Mittelman A. CEA monitoring of palliative treatment for colorectal carcinoma. Ann Surg 1977; 185: 23-30.
21. Aabo K, Pedersen H, Kjaer M. Carcinoembryonic antigen (CEA) and alkaline phosphatase in progressive colorectal cancer with special reference to patient survival. Eur J Cancer Clin Oncol 1986; 22: 211-7.
22. Hamm CM, Cripps C. Carcinoembryonic antigen in metastatic colorectal cancer. Clin Invest Med 1998; 21: 186-91.
23. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
24. Allen-Marsh TG, Kemeny N, Niedzwiecki D, Shurgot B, Daly JM. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 1987; 28: 1625-9.